Loading…

miR-31 and miR-17-5p levels change during transformation of follicular lymphoma

Summary The 30% of patients whose indolent follicular lymphoma transforms to aggressive diffuse large B-cell lymphoma (DLBCL) have poor survival. Reliable predictors of follicular B-cell lymphoma transformation to DLBCL are lacking, and diagnosis of those that will progress is challenging. MicroRNA,...

Full description

Saved in:
Bibliographic Details
Published in:Human pathology 2016-04, Vol.50, p.118-126
Main Authors: Thompson, Mary Ann, MD, PhD, Edmonds, Mick D., PhD, Liang, Shan, MS, McClintock-Treep, Sara, MD, Wang, Xuan, MD, Li, Shaoying, MD, Eischen, Christine M., PhD
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4651-616357ffc7774801f4fcecad478a3b1f7ddf4cfd51d85822faac840c74019daf3
cites cdi_FETCH-LOGICAL-c4651-616357ffc7774801f4fcecad478a3b1f7ddf4cfd51d85822faac840c74019daf3
container_end_page 126
container_issue
container_start_page 118
container_title Human pathology
container_volume 50
creator Thompson, Mary Ann, MD, PhD
Edmonds, Mick D., PhD
Liang, Shan, MS
McClintock-Treep, Sara, MD
Wang, Xuan, MD
Li, Shaoying, MD
Eischen, Christine M., PhD
description Summary The 30% of patients whose indolent follicular lymphoma transforms to aggressive diffuse large B-cell lymphoma (DLBCL) have poor survival. Reliable predictors of follicular B-cell lymphoma transformation to DLBCL are lacking, and diagnosis of those that will progress is challenging. MicroRNA, which regulates gene expression, has critical functions in the growth and progression of many cancers and contributes to the pathogenesis of lymphoma. Using 5 paired samples from patients who presented with follicular lymphoma and progressed to DLBCL, we identified specific microRNA differentially expressed between the two. Specifically, miR-17-5p levels were low in follicular lymphoma and increased as the disease transformed. In contrast, miR-31 expression was high in follicular lymphoma and decreased as the lymphoma progressed. These results were confirmed in additional unpaired cases of low-grade follicular lymphoma (n = 13) and high-grade follicular lymphoma grade 3 or DLBCL (n = 17). Loss of miR-31 expression in DLBCL was not due to deletion of the locus. Changes in miR-17-5p and miR-31 were not correlated with immunophenotype, genetics, or status of the MYC oncogene. However, increased miR-17-5p expression did significantly correlate with increased expression of p53 protein, which is indicative of mutant TP53 . Two pro-proliferative genes, E2F2 and PI3KC2A , were identified as direct messenger RNA targets of miR-31, suggesting that these may contribute to follicular lymphoma transformation. Our results indicate that changes in miR-31 and miR-17-5p reflect the transformation of follicular lymphoma to an aggressive large B-cell lymphoma and may, along with their targets, be viable markers for this process.
doi_str_mv 10.1016/j.humpath.2015.11.011
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4804154</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0046817715004815</els_id><sourcerecordid>1775171263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4651-616357ffc7774801f4fcecad478a3b1f7ddf4cfd51d85822faac840c74019daf3</originalsourceid><addsrcrecordid>eNqFkstu1DAUhi0EokPhEUCR2LBJ8EnsONkUVRUUpEqVuKwt15eJB8cOdjLSvD2OZlqgG1Y-kr_zn8t_EHoNuAIM7ftdNSzjJOahqjHQCqDCAE_QBmhTl13T10_RBmPSlh0wdoZepLTDmaCEPkdnddv3jBC6Qbej_Vo2UAivijUEVtKpcHqvXSrkIPxWF2qJ1m-LOQqfTIijmG3wRTCFCc5ZuTgRC3cYpyGM4iV6ZoRL-tXpPUc_Pn38fvW5vLm9_nJ1eVNK0lIoW2gbyoyRjDHSYTDESC2FIqwTzR0YppQh0igKqqNdXRshZEewZARDr4RpztHFUXda7katpPa5PcenaEcRDzwIy__98Xbg27DnuRrJW8gC704CMfxadJr5aJPUzgmvw5J43hoFBnXbZPTtI3QXlujzeBy63D4B6LtM0SMlY0gpavPQDGC-WsZ3_GQZXy3jADwbkvPe_D3JQ9a9Rxn4cASyJXpvdeRJWu2lVjZqOXMV7H9LXDxSkM56K4X7qQ86_ZmGp5pj_m29m_VsgOaoyxf1Gy1Lv1Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1874841198</pqid></control><display><type>article</type><title>miR-31 and miR-17-5p levels change during transformation of follicular lymphoma</title><source>ScienceDirect Freedom Collection</source><creator>Thompson, Mary Ann, MD, PhD ; Edmonds, Mick D., PhD ; Liang, Shan, MS ; McClintock-Treep, Sara, MD ; Wang, Xuan, MD ; Li, Shaoying, MD ; Eischen, Christine M., PhD</creator><creatorcontrib>Thompson, Mary Ann, MD, PhD ; Edmonds, Mick D., PhD ; Liang, Shan, MS ; McClintock-Treep, Sara, MD ; Wang, Xuan, MD ; Li, Shaoying, MD ; Eischen, Christine M., PhD</creatorcontrib><description>Summary The 30% of patients whose indolent follicular lymphoma transforms to aggressive diffuse large B-cell lymphoma (DLBCL) have poor survival. Reliable predictors of follicular B-cell lymphoma transformation to DLBCL are lacking, and diagnosis of those that will progress is challenging. MicroRNA, which regulates gene expression, has critical functions in the growth and progression of many cancers and contributes to the pathogenesis of lymphoma. Using 5 paired samples from patients who presented with follicular lymphoma and progressed to DLBCL, we identified specific microRNA differentially expressed between the two. Specifically, miR-17-5p levels were low in follicular lymphoma and increased as the disease transformed. In contrast, miR-31 expression was high in follicular lymphoma and decreased as the lymphoma progressed. These results were confirmed in additional unpaired cases of low-grade follicular lymphoma (n = 13) and high-grade follicular lymphoma grade 3 or DLBCL (n = 17). Loss of miR-31 expression in DLBCL was not due to deletion of the locus. Changes in miR-17-5p and miR-31 were not correlated with immunophenotype, genetics, or status of the MYC oncogene. However, increased miR-17-5p expression did significantly correlate with increased expression of p53 protein, which is indicative of mutant TP53 . Two pro-proliferative genes, E2F2 and PI3KC2A , were identified as direct messenger RNA targets of miR-31, suggesting that these may contribute to follicular lymphoma transformation. Our results indicate that changes in miR-31 and miR-17-5p reflect the transformation of follicular lymphoma to an aggressive large B-cell lymphoma and may, along with their targets, be viable markers for this process.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2015.11.011</identifier><identifier>PMID: 26997445</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>3' Untranslated Regions ; Adult ; Aged ; Aged, 80 and over ; B-cell lymphoma ; Binding Sites ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Biopsy ; Cell Line ; Cell Proliferation ; Cell Transformation, Neoplastic - genetics ; Cell Transformation, Neoplastic - metabolism ; Cell Transformation, Neoplastic - pathology ; Child ; Class I Phosphatidylinositol 3-Kinases ; Disease Progression ; DLBCL ; E2F2 Transcription Factor - genetics ; E2F2 Transcription Factor - metabolism ; Female ; Follicular lymphoma ; Gene expression ; Gene Expression Regulation, Neoplastic ; Genetic Predisposition to Disease ; Humans ; Hybridization ; Lymphatic system ; Lymphoma ; Lymphoma, Follicular - genetics ; Lymphoma, Follicular - metabolism ; Lymphoma, Follicular - pathology ; Lymphoma, Large B-Cell, Diffuse - genetics ; Lymphoma, Large B-Cell, Diffuse - metabolism ; Lymphoma, Large B-Cell, Diffuse - pathology ; Male ; MicroRNA ; MicroRNAs ; MicroRNAs - genetics ; MicroRNAs - metabolism ; Middle Aged ; Neoplasm Grading ; Pathology ; Patients ; Phenotype ; Phosphatidylinositol 3-Kinases - genetics ; Phosphatidylinositol 3-Kinases - metabolism ; Polymerase chain reaction ; Software ; Transfection ; Transformation</subject><ispartof>Human pathology, 2016-04, Vol.50, p.118-126</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Apr 01, 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4651-616357ffc7774801f4fcecad478a3b1f7ddf4cfd51d85822faac840c74019daf3</citedby><cites>FETCH-LOGICAL-c4651-616357ffc7774801f4fcecad478a3b1f7ddf4cfd51d85822faac840c74019daf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26997445$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thompson, Mary Ann, MD, PhD</creatorcontrib><creatorcontrib>Edmonds, Mick D., PhD</creatorcontrib><creatorcontrib>Liang, Shan, MS</creatorcontrib><creatorcontrib>McClintock-Treep, Sara, MD</creatorcontrib><creatorcontrib>Wang, Xuan, MD</creatorcontrib><creatorcontrib>Li, Shaoying, MD</creatorcontrib><creatorcontrib>Eischen, Christine M., PhD</creatorcontrib><title>miR-31 and miR-17-5p levels change during transformation of follicular lymphoma</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>Summary The 30% of patients whose indolent follicular lymphoma transforms to aggressive diffuse large B-cell lymphoma (DLBCL) have poor survival. Reliable predictors of follicular B-cell lymphoma transformation to DLBCL are lacking, and diagnosis of those that will progress is challenging. MicroRNA, which regulates gene expression, has critical functions in the growth and progression of many cancers and contributes to the pathogenesis of lymphoma. Using 5 paired samples from patients who presented with follicular lymphoma and progressed to DLBCL, we identified specific microRNA differentially expressed between the two. Specifically, miR-17-5p levels were low in follicular lymphoma and increased as the disease transformed. In contrast, miR-31 expression was high in follicular lymphoma and decreased as the lymphoma progressed. These results were confirmed in additional unpaired cases of low-grade follicular lymphoma (n = 13) and high-grade follicular lymphoma grade 3 or DLBCL (n = 17). Loss of miR-31 expression in DLBCL was not due to deletion of the locus. Changes in miR-17-5p and miR-31 were not correlated with immunophenotype, genetics, or status of the MYC oncogene. However, increased miR-17-5p expression did significantly correlate with increased expression of p53 protein, which is indicative of mutant TP53 . Two pro-proliferative genes, E2F2 and PI3KC2A , were identified as direct messenger RNA targets of miR-31, suggesting that these may contribute to follicular lymphoma transformation. Our results indicate that changes in miR-31 and miR-17-5p reflect the transformation of follicular lymphoma to an aggressive large B-cell lymphoma and may, along with their targets, be viable markers for this process.</description><subject>3' Untranslated Regions</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>B-cell lymphoma</subject><subject>Binding Sites</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biopsy</subject><subject>Cell Line</subject><subject>Cell Proliferation</subject><subject>Cell Transformation, Neoplastic - genetics</subject><subject>Cell Transformation, Neoplastic - metabolism</subject><subject>Cell Transformation, Neoplastic - pathology</subject><subject>Child</subject><subject>Class I Phosphatidylinositol 3-Kinases</subject><subject>Disease Progression</subject><subject>DLBCL</subject><subject>E2F2 Transcription Factor - genetics</subject><subject>E2F2 Transcription Factor - metabolism</subject><subject>Female</subject><subject>Follicular lymphoma</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genetic Predisposition to Disease</subject><subject>Humans</subject><subject>Hybridization</subject><subject>Lymphatic system</subject><subject>Lymphoma</subject><subject>Lymphoma, Follicular - genetics</subject><subject>Lymphoma, Follicular - metabolism</subject><subject>Lymphoma, Follicular - pathology</subject><subject>Lymphoma, Large B-Cell, Diffuse - genetics</subject><subject>Lymphoma, Large B-Cell, Diffuse - metabolism</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Male</subject><subject>MicroRNA</subject><subject>MicroRNAs</subject><subject>MicroRNAs - genetics</subject><subject>MicroRNAs - metabolism</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Pathology</subject><subject>Patients</subject><subject>Phenotype</subject><subject>Phosphatidylinositol 3-Kinases - genetics</subject><subject>Phosphatidylinositol 3-Kinases - metabolism</subject><subject>Polymerase chain reaction</subject><subject>Software</subject><subject>Transfection</subject><subject>Transformation</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkstu1DAUhi0EokPhEUCR2LBJ8EnsONkUVRUUpEqVuKwt15eJB8cOdjLSvD2OZlqgG1Y-kr_zn8t_EHoNuAIM7ftdNSzjJOahqjHQCqDCAE_QBmhTl13T10_RBmPSlh0wdoZepLTDmaCEPkdnddv3jBC6Qbej_Vo2UAivijUEVtKpcHqvXSrkIPxWF2qJ1m-LOQqfTIijmG3wRTCFCc5ZuTgRC3cYpyGM4iV6ZoRL-tXpPUc_Pn38fvW5vLm9_nJ1eVNK0lIoW2gbyoyRjDHSYTDESC2FIqwTzR0YppQh0igKqqNdXRshZEewZARDr4RpztHFUXda7katpPa5PcenaEcRDzwIy__98Xbg27DnuRrJW8gC704CMfxadJr5aJPUzgmvw5J43hoFBnXbZPTtI3QXlujzeBy63D4B6LtM0SMlY0gpavPQDGC-WsZ3_GQZXy3jADwbkvPe_D3JQ9a9Rxn4cASyJXpvdeRJWu2lVjZqOXMV7H9LXDxSkM56K4X7qQ86_ZmGp5pj_m29m_VsgOaoyxf1Gy1Lv1Q</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Thompson, Mary Ann, MD, PhD</creator><creator>Edmonds, Mick D., PhD</creator><creator>Liang, Shan, MS</creator><creator>McClintock-Treep, Sara, MD</creator><creator>Wang, Xuan, MD</creator><creator>Li, Shaoying, MD</creator><creator>Eischen, Christine M., PhD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160401</creationdate><title>miR-31 and miR-17-5p levels change during transformation of follicular lymphoma</title><author>Thompson, Mary Ann, MD, PhD ; Edmonds, Mick D., PhD ; Liang, Shan, MS ; McClintock-Treep, Sara, MD ; Wang, Xuan, MD ; Li, Shaoying, MD ; Eischen, Christine M., PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4651-616357ffc7774801f4fcecad478a3b1f7ddf4cfd51d85822faac840c74019daf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>3' Untranslated Regions</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>B-cell lymphoma</topic><topic>Binding Sites</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biopsy</topic><topic>Cell Line</topic><topic>Cell Proliferation</topic><topic>Cell Transformation, Neoplastic - genetics</topic><topic>Cell Transformation, Neoplastic - metabolism</topic><topic>Cell Transformation, Neoplastic - pathology</topic><topic>Child</topic><topic>Class I Phosphatidylinositol 3-Kinases</topic><topic>Disease Progression</topic><topic>DLBCL</topic><topic>E2F2 Transcription Factor - genetics</topic><topic>E2F2 Transcription Factor - metabolism</topic><topic>Female</topic><topic>Follicular lymphoma</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genetic Predisposition to Disease</topic><topic>Humans</topic><topic>Hybridization</topic><topic>Lymphatic system</topic><topic>Lymphoma</topic><topic>Lymphoma, Follicular - genetics</topic><topic>Lymphoma, Follicular - metabolism</topic><topic>Lymphoma, Follicular - pathology</topic><topic>Lymphoma, Large B-Cell, Diffuse - genetics</topic><topic>Lymphoma, Large B-Cell, Diffuse - metabolism</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Male</topic><topic>MicroRNA</topic><topic>MicroRNAs</topic><topic>MicroRNAs - genetics</topic><topic>MicroRNAs - metabolism</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Pathology</topic><topic>Patients</topic><topic>Phenotype</topic><topic>Phosphatidylinositol 3-Kinases - genetics</topic><topic>Phosphatidylinositol 3-Kinases - metabolism</topic><topic>Polymerase chain reaction</topic><topic>Software</topic><topic>Transfection</topic><topic>Transformation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Mary Ann, MD, PhD</creatorcontrib><creatorcontrib>Edmonds, Mick D., PhD</creatorcontrib><creatorcontrib>Liang, Shan, MS</creatorcontrib><creatorcontrib>McClintock-Treep, Sara, MD</creatorcontrib><creatorcontrib>Wang, Xuan, MD</creatorcontrib><creatorcontrib>Li, Shaoying, MD</creatorcontrib><creatorcontrib>Eischen, Christine M., PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, Mary Ann, MD, PhD</au><au>Edmonds, Mick D., PhD</au><au>Liang, Shan, MS</au><au>McClintock-Treep, Sara, MD</au><au>Wang, Xuan, MD</au><au>Li, Shaoying, MD</au><au>Eischen, Christine M., PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>miR-31 and miR-17-5p levels change during transformation of follicular lymphoma</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>50</volume><spage>118</spage><epage>126</epage><pages>118-126</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><abstract>Summary The 30% of patients whose indolent follicular lymphoma transforms to aggressive diffuse large B-cell lymphoma (DLBCL) have poor survival. Reliable predictors of follicular B-cell lymphoma transformation to DLBCL are lacking, and diagnosis of those that will progress is challenging. MicroRNA, which regulates gene expression, has critical functions in the growth and progression of many cancers and contributes to the pathogenesis of lymphoma. Using 5 paired samples from patients who presented with follicular lymphoma and progressed to DLBCL, we identified specific microRNA differentially expressed between the two. Specifically, miR-17-5p levels were low in follicular lymphoma and increased as the disease transformed. In contrast, miR-31 expression was high in follicular lymphoma and decreased as the lymphoma progressed. These results were confirmed in additional unpaired cases of low-grade follicular lymphoma (n = 13) and high-grade follicular lymphoma grade 3 or DLBCL (n = 17). Loss of miR-31 expression in DLBCL was not due to deletion of the locus. Changes in miR-17-5p and miR-31 were not correlated with immunophenotype, genetics, or status of the MYC oncogene. However, increased miR-17-5p expression did significantly correlate with increased expression of p53 protein, which is indicative of mutant TP53 . Two pro-proliferative genes, E2F2 and PI3KC2A , were identified as direct messenger RNA targets of miR-31, suggesting that these may contribute to follicular lymphoma transformation. Our results indicate that changes in miR-31 and miR-17-5p reflect the transformation of follicular lymphoma to an aggressive large B-cell lymphoma and may, along with their targets, be viable markers for this process.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26997445</pmid><doi>10.1016/j.humpath.2015.11.011</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0046-8177
ispartof Human pathology, 2016-04, Vol.50, p.118-126
issn 0046-8177
1532-8392
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4804154
source ScienceDirect Freedom Collection
subjects 3' Untranslated Regions
Adult
Aged
Aged, 80 and over
B-cell lymphoma
Binding Sites
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Biopsy
Cell Line
Cell Proliferation
Cell Transformation, Neoplastic - genetics
Cell Transformation, Neoplastic - metabolism
Cell Transformation, Neoplastic - pathology
Child
Class I Phosphatidylinositol 3-Kinases
Disease Progression
DLBCL
E2F2 Transcription Factor - genetics
E2F2 Transcription Factor - metabolism
Female
Follicular lymphoma
Gene expression
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Humans
Hybridization
Lymphatic system
Lymphoma
Lymphoma, Follicular - genetics
Lymphoma, Follicular - metabolism
Lymphoma, Follicular - pathology
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Large B-Cell, Diffuse - metabolism
Lymphoma, Large B-Cell, Diffuse - pathology
Male
MicroRNA
MicroRNAs
MicroRNAs - genetics
MicroRNAs - metabolism
Middle Aged
Neoplasm Grading
Pathology
Patients
Phenotype
Phosphatidylinositol 3-Kinases - genetics
Phosphatidylinositol 3-Kinases - metabolism
Polymerase chain reaction
Software
Transfection
Transformation
title miR-31 and miR-17-5p levels change during transformation of follicular lymphoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T01%3A52%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=miR-31%20and%20miR-17-5p%20levels%20change%20during%20transformation%20of%20follicular%20lymphoma&rft.jtitle=Human%20pathology&rft.au=Thompson,%20Mary%20Ann,%20MD,%20PhD&rft.date=2016-04-01&rft.volume=50&rft.spage=118&rft.epage=126&rft.pages=118-126&rft.issn=0046-8177&rft.eissn=1532-8392&rft_id=info:doi/10.1016/j.humpath.2015.11.011&rft_dat=%3Cproquest_pubme%3E1775171263%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4651-616357ffc7774801f4fcecad478a3b1f7ddf4cfd51d85822faac840c74019daf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1874841198&rft_id=info:pmid/26997445&rfr_iscdi=true